Production (Stage)
Fate Therapeutics, Inc.
FATE
$1.28
-$0.125-8.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -12.42% | -39.49% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.42% | -39.49% | |||
| Cost of Revenue | 70.00% | -50.54% | |||
| Gross Profit | -80.03% | 51.61% | |||
| SG&A Expenses | -56.60% | 52.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.20% | -11.87% | |||
| Operating Income | 12.19% | 10.24% | |||
| Income Before Tax | 27.86% | -9.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 27.86% | -9.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.86% | -9.39% | |||
| EBIT | 12.19% | 10.24% | |||
| EBITDA | 10.07% | 11.66% | |||
| EPS Basic | 28.21% | -9.36% | |||
| Normalized Basic EPS | -0.05% | 21.54% | |||
| EPS Diluted | 28.21% | -9.36% | |||
| Normalized Diluted EPS | -0.05% | 21.54% | |||
| Average Basic Shares Outstanding | 0.49% | 0.02% | |||
| Average Diluted Shares Outstanding | 0.49% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||